On August 2, 2023, the U.S. Food and Drug Administration approved trifluridine and tipiracil (LONSURF) with bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in patients who have previously received a
On August 2, 2023, the U.S. Food and Drug Administration approved trifluridine and tipiracil (LONSURF) with bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in patients who have previously received a
More